Pulmonary Embolism
A guide to pulmonary embolism symptoms, diagnostic tests, risk classification, anticoagulation and follow-up.
Pulmonary embolism occurs when a blood clot, usually originating in a deep vein of the leg or pelvis, travels to the pulmonary arteries. The clinical spectrum ranges from small stable emboli to life-threatening obstruction with shock.
Diagnosis and Early Risk
Sudden breathlessness, pleuritic chest pain, coughing blood, fainting or an unexplained rapid pulse may occur. Clinical probability is assessed before D-dimer or imaging is selected. CT pulmonary angiography is commonly used; ultrasound and echocardiography provide additional information in selected patients. Blood pressure, right-ventricular strain, biomarkers and comorbidity guide early risk classification.
Treatment
Anticoagulation is the main treatment for most patients. Thrombolysis, catheter-based therapy or surgery is reserved for haemodynamic instability or selected deteriorating patients after benefit-risk assessment. Treatment duration depends on whether the event was provoked, recurrence risk, bleeding risk and persistent factors.
Follow-up addresses breathlessness, chronic thromboembolic pulmonary hypertension and anticoagulant safety. Call emergency services for sudden breathlessness, fainting, coughing blood or chest pain.
Clinical Depth and Risk Assessment
Risk is not defined by the diagnostic label alone. Symptoms, ECG and rhythm findings, ventricular function, myocardial scar or structural change, family history, associated disease and previous events are integrated. Genetic results, when relevant, require expert interpretation; a variant of uncertain significance is not equivalent to a diagnosis.
Diagnostic Strategy and Limitations
Testing is selected to answer a specific question. ECG, ambulatory monitoring, echocardiography, cardiac MRI, CT, laboratory testing, exercise assessment or invasive evaluation have complementary roles. A normal test may not exclude an intermittent disorder, while an abnormal measurement must be checked against technical quality and clinical probability.
Treatment Decision Framework
Treatment may combine risk-factor control, condition-specific medicines, rhythm or heart-failure therapy, catheter procedures, surgery and implanted devices. These options address different mechanisms and are not automatically substitutes for one another. Expected benefit, uncertainty, procedural burden and the patient’s informed preferences should be discussed explicitly.
Long-Term Follow-up
Follow-up assesses symptoms, exercise capacity, rhythm burden, ventricular function and treatment tolerance over time. Family screening may be appropriate in inherited or suspected inherited disease. New fainting, sustained rapid rhythm, chest pain, neurological symptoms or rapidly worsening breathlessness requires urgent assessment.
Questions to Discuss With the Cardiology Team
- Which finding has the greatest influence on my present risk?
- Which test or treatment would genuinely change management?
- What symptoms should lead to an earlier appointment or emergency care?
- Do relatives need clinical or genetic assessment?
Medical Information Note
This page supports an informed discussion with the clinical team. It does not provide a personal diagnosis, medicine dose or sports-clearance decision.